Bone metastatic disease is common across all breast cancer subtypes, while patients with hormone receptor (HR)-positive breast cancer tend to have the greatest predilection for developing bone metastases (7, 8), unlike organotropic metastasis to visceral organs in HER2-positive and triple-negative breast cancer (TNBC) (9, 10). Here, ERBB2 is linked to breast carcinoma.